JN002

Phase 1Small molecule

EEye & ENT Hospital of Fudan University

JN002 is one of 25 small molecule programs targeting Eye Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eye DiseaseRecruiting

Eye DiseasePhase 1

Recruiting

Competition

Competitive Landscape

29 competitors in Eye Disease

#DrugCompanyPhaseTrials

Chantix

PPrism Pharmaceuticals

Approved

2 2

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

—3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—4

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—5

Empaveli

Apellis Pharmaceuticals

Approved

—6

Heparin Sodium

BBaxter Healthcare Corporation

Approved

—7

Rapamune

PPrism Pharmaceuticals

Approved

—8

Miebo

BBausch & Lomb Incorporated

Phase 3

2 9

AZR-MD-001

AAzura Ophthalmics

Phase 3

2 10

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Eye Disease1 trial

JN002 for the Treatment of Dry Eye Disease

Recruiting·EEye & ENT Hospital of Fudan University·Phase 1·NCT07245017·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JN002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JN002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JN002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eye & ENT Hospital of Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEye & ENT Hospital of Fudan University

JN002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Eye Disease1 trial

References

Drug Info

Quick Facts

Related News